A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (SIERRA)

ClinicalTrials.gov processed this data on November 4, 2024. Link to the current ClinicalTrials.gov record.

Recruitment Status

RECRUITING (See Contacts and Locations)
Verified November 2024 by AstraZeneca

Sponsor

AstraZeneca

Information Provided by (Responsible Party)

AstraZeneca

Clinicaltrials.gov Identifier

NCT05883644
Other Study ID Numbers: D419CR00030
First Submitted: May 22, 2023
First Posted: June 1, 2023
Last Update Posted: November 5, 2024
Last Verified: November 2024
History of Changes

Listing a study on this site does not mean it has been evaluated by the U.S. Federal Government. The safety and scientific validity of a study listed on ClinicalTrials.gov is the responsibility of the study sponsor and investigators. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.

ClinicalTrials.gov, a resource provided by the U.S. National Library of Medicine (NLM), is a registry and results information database of clinical research studies sponsored or funded by a broad range of public and private organizations around the world. Not all studies listed on ClinicalTrials.gov are funded by the National Institutes of Health (NIH) or other agencies of the U.S. Federal Government. Not all listed studies are regulated and/or reviewed by the U.S. Food and Drug Administration or other governmental entities.

Information on ClinicalTrials.gov is provided by study sponsors and investigators, and they are responsible for ensuring that the studies follow all applicable laws and regulations. NLM staff do not verify the scientific validity or relevance of the submitted information beyond a limited quality control review for apparent errors, deficiencies, or inconsistencies.

Choosing to participate in a study is an important personal decision. Before you participate in a study, discuss all options with your health care provider and other trusted advisors. For more information about participating in clinical studies, see Learn About Clinical Studies, which includes questions that you might want to ask before deciding to participate in a study.

For more information about using the information on ClinicalTrials.gov, please also see Terms and Conditions.

See also the Web Policies and Notices for the NIH web site.

Study Description

This is a Phase IIIb, open-label, single arm, multicentre study to assess the safety and efficacy of STRIDE as first-line therapy in participants with advanced unresectable HCC who have one of the following:

Child-Pugh score B7 or B8 with a World Health Organisation Eastern Cooperative Oncology Group Performance Status (WHO/ECOG PS) of 0-1 at enrolment, or

Child-Pugh class A with a WHO/ECOG PS of 2 at enrolment, or

Child-Pugh class A with a WHO/ECOG PS of 0-1 and with evidence of chronic main trunk portal vein thrombosis at enrolment

Participants must not have received any prior systemic therapy for HCC. Participants may have previously received locoregional therapy (LRT) but must no longer be suitable for additional LRT. Any local treatment needs to have been completed at least 4 weeks prior to initiation of treatment. The study consists of 4 periods: screening (Day-28 to Day -1), Treatment period, safety follow-up and survival follow-up.
Condition or Disease Intervention/Treatment
  • Advanced Hepatocellular Carcinoma
  • Drug: Durvalumab
  • Drug: Tremelimumab

Study Design

Study TypeInterventional
Anticipated Enrollment110 participants
Design AllocationN/A
Interventional ModelSingle Group Assignment
MaskingNone (Open Label)
Primary PurposeTreatment
Official TitleA Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (SIERRA)
Study Start DateJune 27, 2023
Anticipated Primary Completion DateJune 30, 2025
Anticipated Study Completion DateDecember 30, 2025

Groups and Cohorts

Group/ CohortIntervention/ Treatment
  • Durvalumab plus Tremelimumab
    • Participants will receive a single priming dose of Tremelimumab plus Durvalumab at Day 1 (Week 0), followed by Durvalumab monotherapy starting at Week 4 and continuing until clinical progression, confirmed RECIST 1.1-defined radiological progression, unacceptable toxicity, withdrawal of consent, or any intervention discontinuation criteria.
  • Drug: Durvalumab
    • Participants will receive 1500 mg at Day 1 and later receive as monotherapy starting at Week 4 for every 4 weeks through IV infusion
  • Drug: Tremelimumab

    Outcome Measures

    Primary Outcome Measures

    1. Incidence of grade 3 or 4 possibly related to treatment adverse events (PRAEs) [From the date of first dose of IMP until 6 months after the initiation of study intervention]
      PRAE is defined as an AE which has been assessed by the investigator to be possibly related to IMP.
    2. Objective response rate (ORR) [From the first dose of IMP until progression, or the last evaluable assessment in the absence of progression [approx. up to 33 months]]
      ORR is defined as the number (%) of participants with a confirmed objective tumour response (complete response [CR] or partial response [PR]) as determined by the investigator per Response Evaluation Criteria in Solid Tumours, Version 1.1 (RECIST 1.1).

    Secondary Outcome Measures

    1. Number of participants with adverse events (AEs), serious adverse events (SAEs), adverse event of special interest (AESIs), immune-mediated AEs (imAEs) [From screening until 90 days following discontinuation of the last dose of IMP [approx. up to 33 months]]
      To assess the safety and tolerability of STRIDE in participants with advanced unresectable HCC
    2. Overall Survival (OS) [From the date of the first dose of IMP until death [maximum follow-up approx. 33 months]]
      OS is defined as the time from the date of the first dose of IMP until death due to any cause.
    3. Progression-Free Survival (PFS) [From the date of the first dose of IMP until the date of objective PD or death [maximum follow-up approx. 33 months]]
      PFS is defined as the time from the first dose of IMP until the date of objective PD (per RECIST 1.1 as assessed by the investigator) or death (by any cause in the absence of progression)
    4. Disease Control Rate at Week 16 (DCR-16w) [At Week 16]
      DCR-16w is defined as the percentage of participants who have a best objective response of complete response or partial response (by Week 16 + 7 days) or who have stable disease for at least 16 weeks (-7 days), following the start of study intervention as determined by the investigator per RECIST 1.1
    5. Disease Control Rate at Week 24 (DCR-24w) [At Week 24]
      DCR-24w is defined as the percentage of participants who have a best objective response of complete response or partial response (by Week 24 + 7 days) or who have stable disease for at least 24 weeks (-7 days), following the start of study intervention per RECIST 1.1
    6. Duration of Response (DOR) [From the date of first documented response until the first date of documented progression or death in the absence of disease progression [approx. up to 33 months]]
      DOR is defined as the time from the date of first documented response until the date of documented progression per RECIST 1.1, as assessed by the investigator or death in the absence of disease progression.
    7. Duration of Treatment (DOT) [From the date of first dose of IMP to the date of last dose of IMP [approx. up to 33 months]]
      DOT is defined as time on study intervention.
    8. Time to deterioration in Health-Related Quality of Life (HRQoL), assessed using the EORTC QLQ C-30. [Every 8 weeks from date of first dose of IMP for the first 48 weeks and then every 12 weeks thereafter until treatment discontinuation and 90 days after last dose during safety follow-up [approx. up to 33 months]]
      Time to deterioration is defined as time from date of first dose of study intervention to the date of the first clinically meaningful deterioration (defined as a a decrease from baseline of at least 10 points for EORTC QLQ-C30 global HRQoL and functional scales, and an increase from baseline of at least 10 points for the EORTC QLQ-C30 symptom scales) that is confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful deterioration. The domains/scales of the EORTC QLQ-C30 prioritized include global health status/QoL, functioning (physical), multi-term symptom (fatigue) and single item symptoms (appetite loss and nausea). Final scores range from 0 to 100, where higher scores on the global measure of health status and functional scales indicate better health status/function, but higher scores on symptom scales represent greater symptom severity.
    9. Clinically meaningful change from baseline in HRQoL as assessed by EORTC QLQ C-30 [Every 8 weeks from date of first dose of IMP for the first 48 weeks and then every 12 weeks thereafter until treatment discontinuation and 90 days after last dose during safety follow-up [approx. up to 33 months]]
      Clinically meaningful change from baseline in global health status/QoL, symptoms and function score (categorized as improvement, no change or deterioration) is defined as an absolute change in the score from baseline of ≥ 10 for scales from the EORTC QLQ-C30 to assess disease and treatment related symptoms and HRQoL.The domains/scales of the EORTC QLQ-C30 prioritized include global health status/QoL, functioning (physical), multi-term symptom (fatigue) and single item symptoms (appetite loss and nausea). Final scores range from 0 to 100, where higher scores on the global measure of health status and functional scales indicate better health status/function, but higher scores on symptom scales represent greater symptom severity.
    10. Best overall response for HRQoL as assessed by EORTC QLQ C-30 [Every 8 weeks from date of first dose of IMP for the first 48 weeks and then every 12 weeks thereafter until treatment discontinuation and 90 days after last dose during safety follow-up [approx. up to 33 months]]
      Best overall response for global health status/QoL, function and symptom (fatigue) will be derived as the best response the participant achieved, based on evaluable electronic patient-reported outcome (ePRO) data collected during the study period to assess disease and treatment related symptoms and HRQoL. The domains/scales of the EORTC QLQ-C30 prioritized include global health status/QoL, functioning(physical), multi-term symptom (fatigue) and single item symptoms (appetite loss and nausea). Final scores range from 0 to 100, where higher scores on the global measure of health status and functional scales indicate better health status/function, but higher scores on symptom scales represent greater symptom severity.
    11. Change from baseline in HRQoL as assessed by EORTC QLQ C-30 [Every 8 weeks from date of first dose of IMP for the first 48 weeks and then every 12 weeks thereafter until treatment discontinuation and 90 days after last dose during safety follow-up [approx. up to 33 months]]
      Change from baseline of global health status/QoL, symptom and functioning scores to assess disease and treatment related symptoms and HRQoL. The domains/scales of the EORTC QLQ-C30 prioritized include global health status/QoL, functioning(physical), multi-term symptom (fatigue) and single item symptoms(appetite loss and nausea). Final scores range from 0 to 100, where higher scores on the global measure of health status and functional scales indicate better health status/function, but higher scores on symptom scales represent greater symptom severity.
    12. Time to deterioration in HRQoL as assessed by EORTC QLQ-HCC18 [Every 8 weeks from date of first dose of IMP for the first 48 weeks and then every 12 weeks thereafter until treatment discontinuation and 90 days after last dose during safety follow-up [approx. up to 33 months]]
      Time to deterioration is defined as time from date of first dose of study intervention to the date of the first clinically meaningful deterioration (defined as an increase from baseline of at least 10 points for EORTC QLQ-HCC18) that is confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful deterioration. The QLQ-HCC18 is an HCC-specific module from the EORTC comprising 18 questions to assess HCC symptoms. The module includes 6 multi-item domain scales and 2 single-item scales. Final scores range from 0 to 100 where higher scores indicate a greater level of symptom severity and a poorer HRQoL. The items prioritized are single items shoulder pain, abdominal pain and abdominal swelling.
    13. Clinically meaningful change from baseline in HRQoL as assessed by EORTC QLQ-HCC18 [Every 8 weeks from date of first dose of IMP for the first 48 weeks and then every 12 weeks thereafter until treatment discontinuation and 90 days after last dose during safety follow-up [approx. up to 33 months]]
      Clinically meaningful change from baseline (categorized as improvement, no change or deterioration) is defined as an absolute change in the score from baseline of ≥ 10 for scales/items from QLQ-HCC18 to assess disease-related symptoms. The single items prioritized are shoulder pain, abdominal pain and abdominal swelling. The EORTC QLQ-HCC18 module is an 18-item questionnaire. All questions have a 4-point scale: "Not at all," "A little," "Quite a bit," and "Very much." For each of the 8 domains (6 multiple-item scales and 2 single-item scales), final scores are transformed such that they range from 0 to 100, where higher scores indicate greater level of symptoms and worse symptom or a poorer HRQoL.
    14. Best overall response for HRQoL as assessed by EORTC QLQ-HCC18 [Every 8 weeks from date of first dose of IMP for the first 48 weeks and then every 12 weeks thereafter until treatment discontinuation and 90 days after last dose during safety follow-up [approx. up to 33 months]]
      Best overall response in single-item symptoms (shoulder pain, abdominal pain, abdominal swelling) will be derived as the best response the participant achieved, based on evaluable ePRO data collected during the study period to assess disease-related symptoms. The single items prioritized are shoulder pain, abdominal pain and abdominal swelling. The EORTC QLQ-HCC18 module is an 18-item questionnaire. All questions have a 4-point scale: "Not at all," "A little," "Quite a bit," and "Very much." For each of the 8 domains (6 multiple-item scales and 2 single-item scales), final scores are transformed such that they range from 0 to 100, where higher scores indicate greater level of symptoms and worse symptom or a poorer HRQoL.
    15. Change from baseline in HRQoL as assessed by EORTC QLQ-HCC18 [Every 8 weeks from date of first dose of IMP for the first 48 weeks and then every 12 weeks thereafter until treatment discontinuation and 90 days after last dose during safety follow-up [approx. up to 33 months]]
      Change from baseline assessment in EORTC QLQ-HCC18 scale/item score at each post baseline assessment. The prioritized single items scores are shoulder pain, abdominal pain and abdominal swelling. The EORTC QLQ-HCC18 module is an 18-item questionnaire. All questions have a 4-point scale: "Not at all," "A little," "Quite a bit," and "Very much." For each of the 8 domains (6 multiple-item scales and 2 single-item scales), final scores are transformed such that they range from 0 to 100, where higher scores indicate greater level of symptoms and worse symptom or a poorer HRQoL.

    Eligibility Criteria

    Ages Eligible for Study 18 Years to 130 Years (Adult, Older Adult)
    Sexes Eligible for Study All
    Accepts Healthy Volunteers No
    Inclusion Criteria
    • Confirmed unresectable HCC based on histopathological findings (prior histological verification confirming HCC is acceptable), or radiological findings in participants with cirrhosis where histopathological confirmation is not clinically feasible
    • Must not have received prior systemic therapy for HCC
    • Participants expected to live 12 weeks or more
    • At least 1 measurable lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter with CT or MRI, and that is suitable for accurate repeated measurements as per RECIST 1.1 guidelines
    • Must not be eligible for LRT for unresectable HCC.
    • Barcelona Clinic Liver Cancer (BCLC) stage B (that is not eligible for locoregional therapy LRT) or stage C
    • Child-Pugh Score classification on liver disease and WHO/ECOG PS at enrolment complying one of the following:
    • Child-Pugh score B7 or B8 with a WHO/ECOG PS of 0-1 at enrolment, without main trunk portal vein thrombosis.
    • Child-Pugh class A with a WHO/ECOG PS of 2 at enrolment, without main trunk portal vein thrombosis (ie, ECOG PS 2 participants with main portal vein tumour thrombosis are excluded from this study).
    • Child-Pugh class A with WHO/ECOG PS of 0-1 at enrolment and with chronic main trunk portal vein thrombosis
    • Participants with hepatitis B virus (HBV) infection must be treated with antiviral therapy prior to enrolment.
    • Participants with hepatitis C virus (HCV) infection must have confirmed diagnosis of HCV characterized by the presence of detectable HCV RNA or anti-HCV upon enrolment
    • Adequate organ and bone marrow function
    • Negative pregnancy test (serum) for women of childbearing potential.
    • Female participants must be 1 year post-menopausal, surgically sterile, or using one highly effective form of birth control
    • Male and Female participants and their partners must use an acceptable method of contraception.
    • Body weight >30 kg
    Exclusion Criteria
    • Any evidence of acute or uncontrolled diseases, chronic diverticulitis or previous complicated diverticulitis, or history of allogeneic organ transplant, which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardise compliance with the protocol
    • Refractory nausea and vomiting, chronic gastrointestinal (GI) disease, inability to swallow a formulated product, or previous significant bowel resection
    • History of symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia
    • History of another primary malignancy except for:
    • Malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention and of low potential risk for recurrence, or
    • Basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or lentigo maligna that has undergone potentially curative therapy, or
    • Adequately treated carcinoma in situ without evidence of disease
    • Persistent toxicities (Common Terminology Criteria for Adverse Events [CTCAE] Grade > 1) caused by previous anticancer therapy
    • Active or prior documented autoimmune or inflammatory disorders, autoimmune pneumonitis, and autoimmune myocarditis
    • History of active primary immunodeficiency
    • History of leptomeningeal carcinomatosis
    • History of hepatic encephalopathy within the past 6 months or requirement for medications to prevent or control encephalopathy
    • Active or prior documented GI bleeding (eg. esophageal varices or ulcer bleeding) within the past 6 months.
    • Clinical judgement of acute main trunk portal vein thrombosis
    • History of previous, or current, brain metastases or spinal cord compression
    • Known fibrolamellar hepatocellular carcinoma (HCC), sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
    • Clinically meaningful ascites
    • Participants co-infected with HBV and HCV or co-infected with HBV and hepatitis D virus (HDV)
    • Known to have tested positive for human immunodeficiency virus (HIV) or active tuberculosis infection
    • Any concomitant medication known to be associated with Torsades de Pointes
    • Prior exposure to immune-mediated therapy excluding therapeutic anticancer vaccines
    • Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab
    • Receipt of live attenuated vaccine within 30 days prior to the first dose of study intervention" and "Major surgical procedure (as defined by the investigator) or significant traumatic injury within 4 weeks of the first dose of study intervention.

    Contacts and Locations

    Sponsors and Collaborators AstraZeneca
    Locations
    • Research Site | La Jolla, California, United States, 92093
    • Research Site | Shreveport, Louisiana, United States, 71103
    • Research Site | Detroit, Michigan, United States, 48202
    • Research Site | Bobigny, France, 93000
    • Research Site | Clichy, France, 92110
    • Research Site | Creteil, France, 94010
    • Research Site | Lyon, France, 69004
    • Research Site | Marseille, France, 13005
    • Research Site | Rennes, France, 35000
    • Research Site | Berlin, Germany, D-13353
    • Research Site | Frankfurt, Germany, 60488
    • Research Site | Köln, Germany, 50937
    • Research Site | Lübeck, Germany, 23538
    • Research Site | Magdeburg, Germany, 39120
    • Research Site | Mannheim, Germany, 68167
    • Research Site | Hong Kong, Hong Kong, 0000
    • Research Site | Shatin, Hong Kong, 00000
    • Research Site | Milano, Italy, 20132
    • Research Site | Napoli, Italy, 80147
    • Research Site | Padova, Italy, 35128
    • Research Site | Pisa, Italy, 56126
    • Research Site | Rozzano, Italy, 20089
    • Research Site | Turin, Italy, 10128
    • Research Site | Chiba-shi, Japan, 260-8677
    • Research Site | Chuo-ku, Japan, 104-0045
    • Research Site | Kanazawa-shi, Japan, 920-8641
    • Research Site | Kashiwa, Japan, 277-8577
    • Research Site | Kyoto-shi, Japan, 602-8566
    • Research Site | Matsuyama-city, Japan, 790-0024
    • Research Site | Musashino-shi, Japan, 180-8610
    • Research Site | Osakasayama-shi, Japan, 589-8511
    • Research Site | Yokohama-shi, Japan, 241-8515
    • Research Site | Gyeonggi-do, Korea, Republic of, 13620
    • Research Site | Seongnam-si, Korea, Republic of, 13496
    • Research Site | Seoul, Korea, Republic of, 03080
    • Research Site | Seoul, Korea, Republic of, 03722
    • Research Site | Seoul, Korea, Republic of, 05505
    • Research Site | Seoul, Korea, Republic of, 06351
    • Research Site | Singapore, Singapore, 119228
    • Research Site | Singapore, Singapore, 169610
    • Research Site | Singapore, Singapore, 308433
    • Research Site | Barcelona, Spain, 08036
    • Research Site | Barcelona, Spain, 8035
    • Research Site | Cordoba, Spain, 14004
    • Research Site | Madrid, Spain, 28007
    • Research Site | Madrid, Spain, 28040
    • Research Site | Pamplona, Spain, 31008
    • Research Site | Hanoi, Vietnam, 100000
    • Research Site | Ho Chi Minh, Vietnam, 700000
    Investigators
    • Principal Investigator: Stephen Chan, MD, Department of Clinical Oncology, Chinese University of Hong Kong
    • Principal Investigator: Lorenza Rimassa, MD, Humanitas Cancer Centre, IRCCS Humanitas Research Hospital

    More Information

    Additional Relevant MeSH Terms

    • Carcinoma
    • Carcinoma, Hepatocellular
    • Neoplasms, Glandular and Epithelial
    • Neoplasms by Histologic Type
    • Neoplasms
    • Adenocarcinoma
    • Liver Neoplasms
    • Digestive System Neoplasms
    • Neoplasms by Site
    • Digestive System Diseases
    • Liver Diseases